This CPB has been revised to state that: (i) leuprolide acetate (Fensolvi) is considered medically necessary for the treatment of central precocious puberty (CPP) and gender dysphoria when criteria are met, (ii) precertification is required for Zoladex (goserelin acetate implant) for medically necessary indications.